Health News

Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease

Author: Australian Business

LONDON, November 12, 2013 /PRNewswire/ -- Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that it has filed an investigational new drug (IND) application with the US Food and Drug......

More...

More Articles...

Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation by the US FDA for AFN-1252 and Completion of Dosing of AFN-1720 Phase 1 Trial
Helsinn and Chugai Pharma Marketing Enter into Agreement for Rights of Anamorelin, Currently in Development for Treatment of Anorexia-Cachexia Syndrome Related to Non-small Cell Lung Cancer in top EU Markets
Face the Holidays with the Finest in Facial Rejuvenation
Kaiser Permanente's Top-Rated Medicare Plan Website Unveils New Seminar Search Tool
Crothall Healthcare Performance Center Opens National Call Center's "Virtual" Logistical Support Drives Throughput Efficiency
Dynatronics To Release Fiscal First Quarter Results Thursday, November 14, 2013;
Array BioPharma To Present At The Jefferies 2013 Global Healthcare And Piper Jaffray 25th Annual Healthcare Conferences
American College of Surgeons and Arizona Health Care Leaders Share Successes, Identify Areas of Improvement in Surgical Quality Improvement Programs
Ixoreal Biomed "Adopts" Ashwagandha through the American Botanical Council
Northwest Healthcare Symposium To Feature National Panelists To Help Attendees Navigate The World Health Organization's (WHO) 10th Revision Of The International Statistical Classification Of Diseases And Related Health Problems (ICD-10)

Page 680 of 1908